Correlation between chemotherapy response score (CRS) and germline BRCA1/2 (gBRCA) status in women diagnosed with FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)

被引：0
|
作者：
Netto, D. [1 ]
Wang, X. [2 ]
Barnes, B. [3 ]
Clamp, A. R. [1 ]
Hasan, J. [1 ]
Mitchell, C. L. [1 ]
Salih, Z. [1 ]
Winter-Roach, B. [4 ]
Edmondson, R. [3 ]
Shaw, J. [5 ]
Desai, S. [6 ]
Schlecht, H. [7 ]
Burghel, G. J. [8 ]
Taylor, S. [9 ]
Evans, G. [10 ]
Jayson, G. C. [11 ]
Morgan, R. D. [1 ]
机构：
[1] Christie NHS Fdn Trust, Med Oncol Dept, Manchester, Lancs, England
[2] Christie NHS Fdn Trust, Stat, Manchester, Lancs, England
[3] Univ Manchester, Div Canc Sci, Manchester, Lancs, England
[4] Christie NHS Fdn Trust, Surg Oncol, Manchester, Lancs, England
[5] Manchester Univ NHS Fdn Trust, Histopathol, Manchester, Lancs, England
[6] Christie NHS Fdn Trust, Pathol, Manchester, Lancs, England
[7] Manchester Univ NHS Fdn Trust, Genom, Wythenshawe Hosp, Manchester, Lancs, England
[8] GLH North West Genom Lab Hub, North West Genom Lab Hyb, Manchester, Lancs, England
[9] Univ Manchester, Manchester Canc Res Ctr, Manchester, Lancs, England
[10] Manchester Univ NHS Fdn Trust, Clin Genet, Manchester, Lancs, England
[11] Univ Manchester, Med Oncol, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1960
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
782P
引用
收藏
页码：S527 / S528
页数：2
相关论文
共 50 条
  • [21] Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
    Xia Xu
    Fei Deng
    Mengmeng Lv
    Binhui Ren
    Wenwen Guo
    Xiaoxiang Chen
    Journal of Ovarian Research, 9
  • [22] Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
    Christie, Elizabeth L.
    Fereday, Sian
    Doig, Ken
    Pattnaik, Swetansu
    Dawson, Sarah-Jane
    Bowtell, David D. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (12) : 1274 - 1280
  • [23] Oncologists’ perspectives of telephone genetic counseling to facilitate germline BRCA1/2 testing for their patients with high-grade serous ovarian cancer
    Pierre Hemming
    Rajneesh Kaur
    Bettina Meiser
    Joanne McKinley
    Mary-Anne Young
    Paul A. James
    Laura E. Forrest
    Journal of Community Genetics, 2021, 12 : 449 - 457
  • [24] Oncologists' perspectives of telephone genetic counseling to facilitate germline BRCA1/2 testing for their patients with high-grade serous ovarian cancer
    Hemming, Pierre
    Kaur, Rajneesh
    Meiser, Bettina
    McKinley, Joanne
    Young, Mary-Anne
    James, Paul A.
    Forrest, Laura E.
    JOURNAL OF COMMUNITY GENETICS, 2021, 12 (03) : 449 - 457
  • [25] Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
    Xu, Xia
    Deng, Fei
    Lv, Mengmeng
    Ren, Binhui
    Guo, Wenwen
    Chen, Xiaoxiang
    JOURNAL OF OVARIAN RESEARCH, 2016, 9
  • [26] Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain
    Moya-Alarcon, Carlota
    Gonzalez-Dominguez, Almudena
    Simon, Susana
    Perez-Roman, Ines
    Gonzalez-Martin, Antonio
    Bayo-Lozano, Eloisa
    Beatriz Sanchez-Heras, Ana
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (08): : 1076 - 1084
  • [27] Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC)
    Wijaya, Silvana
    Bchir, Mb
    Loh, Jerold
    Lim, Diana
    Wong, Soon Boon Justin
    Low, Jeffrey
    Ng, Joseph
    Tong, Pearl
    Ilancheran, Arunachalam
    Lim, Yi Wan
    Lim, Siew Eng
    Wijaya, Silvana
    Tan, David
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S98 - S98
  • [28] Tumor-infiltrating lymphocytes expression in stage IIIc/IV of high-grade serous ovarian cancer: Variation with neoadjuvant chemotherapy and prognostic value
    Barcena, C.
    Rojas, K.
    Lema, L.
    Manso Sanchez, L.
    Rios, J.
    Garcia-Martin, R.
    Maroto, A.
    Rodriguez-Peralto, J. L.
    Ciruelos Gil, E. M.
    Mendiola, D. C.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas
    Dowson, Cassandra B.
    Stewart, Colin
    O'Sullivan, Sarah
    Pachter, Nicholas
    Schofield, Lyn
    Cohen, Paul A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (01) : 94 - 99
  • [30] Testing unselected women with newly diagnosed high-grade serous ovarian cancer (HGSOC) for germline pathogenic variants (PVs) in mismatch repair (MMR) genes is unnecessary
    Spurgeon, L.
    Burghel, G. J.
    Schlecht, H.
    Clamp, A. R.
    Hasan, J.
    Mitchell, C. L.
    Salih, Z.
    Woodward, E. R.
    Crosbie, E.
    Taylor, S.
    Jayson, G. C.
    Evans, G. D.
    Morgan, R. D.
    ANNALS OF ONCOLOGY, 2024, 35 : S585 - S586
12345